National Science Centre
Finding the factors that control the blood formation process at such an early stage is of enormous importance, not only scientific, but also practical. Abnormal differentiation of hematopoietic cells underlies many diseases, such as leukemia, immune disorders, and some anemia. The possibility of "undoing" cell differentiation offers a technological opportunity to create new therapies and may find application in obtaining material for bone marrow transplants and other treatments.
The experiments will be conducted with the use of human bone marrow derived MSCs. The effect of ibuprofen on MSC cells will be analyzed by comparing the MSCs cultured in the presence of ibuprofen (test samples) to the control samples (MSC cultured under standard conditions). For this purpose, a series of tests will be carried out, which will allow to identify genes and proteins, the expression of which changes under the influence of the drug we use. An experiment will also be performed in which MSC cells will be cultured together with macrophages (cells of the immune system responsible for "eating" of microorganisms that have penetrated into our body and also take part in regenerative processes). Thanks to this, it will be possible to determine if and how ibuprofen influences the interactions between the two populations of cells.
The results of our research project may contribute to the development of new methods of preventing and treating cardiovascular diseases - methods based on the use of piezolites and osmolytes as drugs or dietary supplements.
The study will enable a detailed analysis of the obtained data in the direction of correlation with the frequency of GvHD and infectious complications as well as mortality related to transplantation. The new information will help future development of methods for monitoring the health of the digestive system and strategies to maintain the composition of the intestinal microflora and the tightness of the intestinal barrier, and improve the treatment outcomes of patients after hematopoietic cell transplantation.
In this project, we will investigate the role of Treg and IDO in CLL using a mouse model of the disease that very well reflects the immune system dysfunction observed in CLL patients. We want to answer the following questions: (1) do Treg lymphocytes influence leukemia progression? (2) how does the elimination of Treg lymphocytes affect the number and function of effector T lymphocytes and antigen presenting cells? (3) what is the role of IDO in Treg cell accumulation during leukemia progression?, (4) does IDO affect leukemia progression? (5) whether and how inhibition of IDO affects the functions of other cells of the immune system?